- Industry Size (2022)
- USD 3.3 Bn
- Forecast (2032)
- USD 4.7 Bn
- CAGR (2022 to 2032)
- 3.5%
Preclinical Imaging Market Snapshot (2022 to 2032)
The global preclinical imaging market is expected to enjoy a valuation of US$ 3.3 Billion in 2022, and further expand at a CAGR of 3.5% to reach a valuation of US$ 4.7 Billion by the end of the year 2032. According to a recent study by Future Market Insights, MRI imaging is leading the market with a share of about 18.9% in the year 2021, within the global preclinical imaging market.
Market Outlook:
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 3.2 Billion |
|
Market Value 2022 |
US$ 3.3 Billion |
|
Market Value 2032 |
US$ 4.7 Billion |
|
CAGR 2022 to 2032 |
3.5% |
|
Market Share of Top 5 Countries |
55.9% |
|
Key Market Players |
Bruker Corporation, Siemens A.G., General Electric (GE), TriFoil Imaging, PerkinElmer, Inc., VisualSonics Inc. (Fujifilm), Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, Molecules |
Over the past decade, preclinical imaging has developed into an important method for biological discoveries. High-frequency micro-ultrasound has developed gradually as a rapid and reasonably priced imaging tool for studying human disease models in small organisms in the post-genomic era.
According to a report published in the Radiology Journal by the University of Cincinnati Medical Center, in 2020, academic medical centers and universities rushed to suspend scientific research initiatives in order to maximize social distance and reduce the spread of infection to research employees and those with whom they might come into contact, in addition to clinical preparedness. Researchers in the field of radiology were debating these problems, which will continue to have an impact on current and upcoming imaging experiments.
Sales Analysis of Preclinical Imaging Market from 2016 to 2021 Vs Market Outlook for 2022 to 2032
The market value for the preclinical imaging market was approximately 11.4% of the overall US$ 28.2 Billion of the global medical imaging market in 2021.
The sales of the preclinical imaging market expanded at a 3.8% CAGR over the historic period of 2016 to 2021.
Preclinical imaging techniques completely follow the 3R (replacement, reduction, and refinement) tenets by lowering biological variability, gathering an extraordinary amount of unique information in multiple ways, and dramatically lowering the number of animals required for a given study.
The market for preclinical imaging is expected to be propelled due to increased investment in research and development for technological advancements in the fields of molecular imaging.
For Instance
To meet the growing need for antiviral research tools and to enable the testing of coronavirus vaccines and treatments, MILabs upgraded their preclinical diagnostic U-CT system for in vivo imaging of COVID-19 animal models in March 2020.
The multimodal imaging technique is gaining importance for the diagnosis of certain diseases. It also helps the physician to perform tests, and plan and guide the therapy.
Pre-symptomatic identification, targeted therapy, and personalized medicine will very soon comply with multimodal molecular imaging's rapid technological advancements.
Another driver that is expected to fuel the preclinical research market’s expansion is the growing number of clinical research organizations (CROs) and pharmaceutical organizations, which are quickly adapting to in-vivo imaging systems for pre-clinical research.
For instance
In July 2020, the USF Health Morsani College of Medicine installed their new 7T-3T MR/PET and PET-CT systems by MR solutions to create their first thorough preclinical imaging suite.
What are the Key Opportunities for the Preclinical Imaging Product Manufacturers?
The market is set to present an opportunistic outlook, owing to an increasing number of preclinical imaging tests and new alternative methods of testing in the market such are in vitro assays, micro-dosing, computer-based models, virtual drug testing, and the creation of computerized databases for testing. Such strategies will provide the market an opportunity to expand, even in regions with low market penetration right now. New non-invasive imaging modalities are also entering the market to provide better options.
The growth will further be propelled by the increased initiative by public and private organizations for funding to accelerate preclinical research leading to the overall boost of the current market. Additionally, it is anticipated that significant investments made to promote the use of pre-clinical devices will fuel market expansion.
What are the Factors Restraining Demand for Preclinical Imaging Products?
Although the preclinical imaging market has numerous end-users, there are certain obstacles that likely pose a challenge to market growth.
The stringent regulatory framework and the technical and procedural restrictions connected with autonomous systems are predicted to decline the market growth.
In addition, the evidence-based clinical trial and the various challenges posed by the animal rights activist while performing animal testing in the preclinical research will also restrain the growth of the market in the forecast period.
These propose an adverse consequence on the formative development of the preclinical imaging market.
State-of-the-art imaging technologies provided by key players in the USA
North America holds a revenue share of 32.3% and is the largest preclinical imaging market. This is attributed to the vast advancements in the research and development Research and Development sectors due to high investments, strong infrastructure, the presence of multiple private and public organizations, several preclinical initiatives underway, and greater acceptance rates for technologically advanced products.
A major player, namely NYU Langone’s Preclinical Imaging Laboratory, provides investigators with access to advanced imaging technologies and strategies to image live animals on the organ, tissue, cell, or molecular level. Moreover, the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership was announced by the National Institutes of Health (NIH) to establish a coordinated research strategy for prioritizing and speeding the development of the most promising treatments and vaccines.
To diversify their product portfolio, corporations are offering new products. For instance, a key market player announced the debut of the Ultima Investigator Plus in March 2022, which is the newest modular platform addition to the industry-leading Ultima range of multiphoton microscopes for deep tissue fluorescence imaging. These factors are expected to boost the global preclinical imaging market size.
German market players are revolutionizing the market with anatomical, functional and molecular imaging
Europe is the second leading market owing to the rising number of market players who are investing in government initiatives for encouraging clinical research and development projects in this region. Market players in Germany are offering versatile and highly specific contrast from a variety of tissue-intrinsic and extrinsic molecules, including hemoglobin, melanin, lipids, collagen, fluorophores, and nanoparticles. This allows for anatomical, functional, and molecular imaging within a single modality.
These key players are further showing unprecedented performance in terms of combining high resolution and sensitivity. Moreover, they provide new insights into a variety of diseases with the ability to visualize and quantify sub-organ structures at several centimeters of depth. These insights are estimated to contribute to the demand for preclinical imaging in Germany.
Bruker, a major German player, announced the first customer installation of its MPI Preclinical, which is a preclinical Magnetic Particle Imaging (MPI) scanner at the University Medical Center Hamburg-Eppendorf (UKE), Germany. Additionally, this marks the first time that MPI technology has been delivered in a commercial system, as preclinical MPI is an entirely new technology for in vivo imaging of small animals used in translational research.
United Kingdom witnesses the launch of new centers for translational cardiovascular imaging linking basic science
The increasing awareness amongst healthcare professionals and the rise in the number of in vivo molecular diagnostics are the reasons for the rising demand for preclinical imaging. For instance, Edinburgh Preclinical Imaging is a state-of-the-art facility that provides non-invasive, in vivo imaging of the structure and function of all organs and tissues of the body. Furthermore, the facility is within the campus at Little France, where it is ideally placed to provide cross-disciplinary work in cardiovascular biology, physiology, and neuroscience, which stabilizes the adoption of preclinical imaging in the United Kingdom
The British Heart Foundation awarded £ 1.9 Million to support the development of a new center for translational cardiovascular imaging that links basic science and preclinical and clinical cardiovascular research in Leeds and promotes rapid translation from molecular to clinical cardiovascular research. In addition, magnetic resonance imaging (MRI) is a versatile technology that provides sensitivity to a wide range of biologically relevant information.
Preclinical trials using rodent and nonhuman primate models in Japan
The Asia Pacific is a growing lucrative preclinical imaging market, paying owing to factors such as low research costs, less-stringent regulatory guidelines, and increased government funding for the development of the research and development sector in the respective countries are making the region attractive for preclinical research studies.
Japan is experiencing a super-aging ;society both in rural and urban areas, as stated according to the Statistics Bureau of Japan. In addition, the healthcare industry in Japan has well adopted new innovations and advancements for diagnosis, which aids in the growth of the global preclinical imaging market size.
Hamamatsu Pharma Research Inc., a major Japanese market player, performs preclinical trials using rodent and nonhuman primate (NHP) models to judge the efficacy of pharmaceuticals. Furthermore, personalized medicine is emerging as a new goal in the diagnosis and treatment of diseases in Japan, which aims to establish differences between patients suffering from the same disease, which allows them to choose the most effective treatment.
In November 2021, an article titled Developing diagnostic reference levels in Japan was published in the Japanese Journal of Radiology, which indicated that the use of radiological tests in the nation has been increasing significantly in recent years. Similarly, an article published by the Public Relations Office of the Government of Japan in February 2021 stated that the percentage of people over the age of 65 years old in Japan is expected to reach 33.3% by the year 2036 and 38.4% by the year 2065. Hence, the preclinical imaging market share is likely to experience growth owing to these initiatives.
10-year commitment funds by the South Korean government for biotechnology industry
Diagnostic centers in South Korea usually consist of multiple inter-related research groups for the integration of experimental approaches from a diversity of disciplines such as Physics, Chemistry, and Engineering. Each sector assists in developing novel methods and materials for brain research.
10-year commitment funds have been made by the South Korean government to develop their biotechnology industry by building 15 Clinical Trial Centers (CTCs) at major teaching hospitals. These CTCs have avant-garde facilities to perform studies involving the confinement of study participants under highly controlled required for many early clinical research studies where the demand for preclinical imaging and its research is anticipated to develop.
Most healthcare professionals in South Korea are highly educated medical and scientific staff who are interested in early clinical research. Therefore, South Korean scientists are gaining rapid credibility among global clinical pharmacologists, as reflected by higher numbers of publications in leading medical research journals and presentations at leading scientific meetings for clinical pharmacologists.
Country-wise Insights
What Makes the USA a Highly Lucrative Market for Preclinical Imaging Products?
With the vast advancements in the research and development sectors due to high investments, strong infrastructure, presence of multiple private and public organizations, several preclinical initiatives underway, and greater acceptance rates for technologically advanced products the USA holds a global market share of about 32.3% in 2021 and is expected to continue the same through the forecast period.
In April 2020, the National Institutes of Health (NIH) announced the Expediting COVID-19 Therapeutic Interventions and Vaccinations (ACTIV) public-private partnership to build a coordinated research approach for prioritizing and accelerating the development of the most effective drugs and vaccines. This will utilize all high-throughput screening techniques to screen the samples and enhance the efficiency of the scientists, which will inspire the use of such fast-track groups of prominent scientists from government, business, non-profit, charitable, and academic institutions.
What is the outlook of the United Kingdom for the Preclinical Imaging Market?
The United Kingdom is expected to grow at a CAGR of 3.0% in the European market over the forecast period.
The market is anticipated to benefit from the rising number of market players who are investing, and government initiatives for encouraging clinical research and development projects in these regions.
What makes Germany a demanding market for Preclinical Imaging?
Germany holds a global market share of 6.6% and is expected to grow with a CAGR of 3.8% during the forecasted period.
The reason for the rising demand and growth for the preclinical imaging market in the country is the increasing awareness among healthcare professionals, the rise in the number of in-vivo molecular diagnostics, and advanced multi-modal devices with increased sensitivity that are enhanced by digitalization.
Category-wise Insights
Which Preclinical Imaging Product is driving the Market?
MRI imaging held a market share of around 18.9% in the global market in 2021 and the segment is set to grow at a CAGR of 5.5% throughout the forecast period.
The rising prevalence of chronic diseases like cardiovascular, neurological, orthopedic, and cancer, is leading to the rising adoption of MRI imaging procedures across the globe. The introduction of technologically advanced equipment in the market as well as the use of AI-based devices for rapid diagnosis enhance the market growth.
Which Application of Preclinical Imaging is Largely in Focus Globally?
The research and development sector has shown increased demand with a market share of 54.3% globally in 2021 and is expected to grow with a CAGR of 3.0% over the forecasted years.
With innovative technologies in the market, to draw conclusions for human medicine, researchers are thrilled to examine the structure of animal bodies. As a result, research into animal tissues, cells, molecular dynamics, and organs has accelerated recently.
Which End User Benefits the most from the Adoption of Preclinical Imaging?
Biotech companies hold the highest global market share value of 30.4% during the year 2021. Biotech companies are using this opportunity as an essential part of these research and development efforts to bridge molecular discoveries and clinical applications in diagnostics and/or therapies.
Competitive Landscape
With several competitors in the production of compression therapy products, the overall market is highly fragmented. Key Players such as Bruker Corporation, and Siemens A.G. are adopting new strategies like collaborations, the launch of new high–tech products, and partnerships to promote their products.
These strategies are henceforth being followed by upcoming players to increase their business, and capture the untapped markets.
The following are examples of key development strategies used by industry players in the preclinical imaging market:
- Bruker announced the release of the Ultima Investigator Plus, the most recent flexible platform addition to the leading-edge Ultima line of multiphoton microscopes for deep tissue fluorescence imaging, in March 2022. With a wider field of view, improved optics for two and three photon imaging, and a longer close-coupled collection path, the researcher improves scientists' capacity to image deeply and see more inside specimens.
- The Vega imaging system, a first-of-its-kind ultrasound platform that combines hands-free, automated technology with the high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology, and more, was introduced in April 2022, as part of PerkinElmer's announcement of the expansion of its in vivo imaging portfolio.
Similarly, recent developments related to companies manufacturing preclinical imaging products have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope as per Preclinical Imaging Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2022 to 2032 |
|
Historical Data Available for |
2016 to 2021 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
|
Key Countries Covered |
USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, Israel, Turkey, North Africa, and South Africa |
|
Key Market Segments Covered |
Product, Application, End User, and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered in Compression Therapy Industry Research
By Product:
- CT Imaging
- MRI Imaging
- PET/SPECT Imaging
- Multi-modal Imaging
- Optical Imaging
- Ultrasound Imaging
- Photoacoustic Imaging
By Application:
- Research and Development
- Drug Discovery
By End-Users:
- Biotech Companies
- Pharmaceutical companies
- Research institutes
- Contract Research Organizations
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Frequently Asked Questions
How much is the preclinical imaging market worth in 2021?
The global preclinical imaging market is worth US$ 3.2 Billion in 2021 and is set to expand 1.4X over the next ten years.
What is the sales forecast for preclinical imaging market through 2032?
The preclinical imaging market is expected to reach US$ 4.7 Billion by the end of 2032, with sales revenue expected to register a 3.5% CAGR.
What are the key trends shaping the preclinical imaging industry?
The expanding research and development in preclinical imaging devices, increasing funds, rise in the number of in vitro and in vivo tests, and a large number of CROs are some of the key trends shaping the preclinical imaging market.
Which are the top 5 countries driving demand for preclinical imaging market?
The USA, United Kingdom, Germany, China, and Japan are the top 5 countries and are expected to drive demand for the preclinical imaging industry.
What is the North American market outlook for preclinical imaging market?
North America is one of the key markets for preclinical imaging in the year 2021, with a market share accounting for 33.6%.
At what percentage is the demand for preclinical imaging expected to register growth in Europe?
Demand for preclinical imaging in Europe is expected to register a growth of 3.6% CAGR over the next ten years.
Which countries are the key producers of preclinical imaging market?
The USA, Germany, and the United Kingdom are the key producers of the preclinical imaging market.
At what percentage is the demand for preclinical imaging expected to register growth in South Asia?
Demand for preclinical imaging in South Asia is expected to register a growth of 2.9% CAGR over the next ten years.
At what percentage is the demand for preclinical imaging expected to register growth in East Asia?
Demand for preclinical imaging in East Asia is expected to register a growth of 4.4% CAGR over the next ten years.
Who are the key players in the preclinical imaging market sphere?
Bruker Corporation, Siemens A.G., General Electric (GE), TriFoil Imaging, PerkinElmer, Inc., VisualSonics Inc. (Fujifilm), Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, and Molecubes, are some of the key players in the preclinical imaging market.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
1. Executive Summary | Preclinical Imaging Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Development and Innovation Trends
4. Key Success Factors
4.1. Product Adoption/ Usage Analysis
4.2. Regulatory Scenario
4.3. Product Features/ USP’s Analysis
4.4. PESTLE Analysis
4.5. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Industry Market Outlook
5.1.3. Global Clinical Imaging Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Demand for Advanced Molecular Diagnostics
5.2.2. Growing Global Burden of Disease
5.2.3. Growing Investments in Preclinical Research
5.2.4. Innovation and Development
5.2.5. Increased Mergers and Acquisitions
5.2.6. Adoption Rate of Preclinical Research
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1. COVID19 and Impact Analysis
6.1.1. Revenue By Product
6.1.2. Revenue By Application
6.1.3. Revenue By End User
6.1.4. Revenue By Region
6.2. 2021 Market Scenario
7. Global Market Volume (Units) Analysis 2016 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Volume (Units) Analysis, 2016 to 2021
7.2. Current and Future Market Volume (Units) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Pricing Break-up
8.2.1. Manufacturer-Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Value (US$ Billion) Analysis 2016 to 2021 and Forecast, 2022 to 2032
9.1. Historical Market Value (US$ Billion) Analysis, 2015 to 2021
9.2. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Billion) and Volume (Units), By Product, 2016 to 2021
10.3. Current and Future Market Size (US$ Billion) and Volume (Units) Analysis By Product, 2022 to 2032
10.3.1. CT Imaging
10.3.2. MRI Imaging
10.3.3. PET/SPECT Imaging
10.3.4. Multi-modal Imaging
10.3.5. Optical Imaging
10.3.6. Ultrasound Imaging
10.3.7. Photoacoustic Imaging
10.4. Market Attractiveness Analysis By Product
11. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application
11.1. Introduction / Key Findings
11.2. Current and Future Market Size (US$ Billion) and Volume (Units) Analysis and Forecast By Application, 2022 to 2032
11.2.1. Research and Development
11.2.2. Drug Discovery
11.3. Market Attractiveness Analysis By Application
12. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Billion), By End User, 2016 to 2021
12.3. Current and Future Market Size (US$ Billion) and Forecast By End User, 2022 to 2032
12.3.1. Biotech Companies
12.3.2. Pharmaceutical companies
12.3.3. Research institutes
12.3.4. Contract Research Organizations
12.4. Market Attractiveness Analysis By End User
13. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Billion) and Volume (Units) Analysis By Region, 2016 to 2021
13.3. Current Market Size (US$ Billion) and Volume (Units) Analysis and Forecast By Region, 2022 to 2032
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2016 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Billion) ) and Volume (Units) Analysis, By Market Taxonomy, 2016 to 2021
14.3. Current and Future Market Size (US$ Billion) ) and Volume (Units) Analysis, By Market Taxonomy 2022 to 2032
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Application
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Product
14.4.2. By Application
14.4.3. By End User
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. USA Market Analysis
14.7.1.1. .Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Product
14.7.1.2.2. By Application
14.7.1.2.3. By End User
14.7.2. Canada Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Product
14.7.2.2.2. By Application
14.7.2.2.3. By End User
15. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Billion) and ) and Volume (Units) Analysis By Market Taxonomy, 2016 to 2021
15.3. Current and Future Market Size (US$ Billion) ) and Volume (Units) Analysis, By Market Taxonomy, 2022 to 2032
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Application
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Product
15.4.2. By Application
15.4.3. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Brazil Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Application
15.7.1.2.3. By End User
15.7.2. Mexico Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Application
15.7.2.2.3. By End User
15.7.3. Argentina Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Product
15.7.3.2.2. By Application
15.7.3.2.3. By End User
16. Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Billion) and Volume (Units) Analysis, By Market Taxonomy, 2016 to 2021
16.3. Current and Future Market Size (US$ Billion) ) and Volume (Units) Analysis, By Market Taxonomy, 2022 to 2032
16.3.1. By Country
16.3.1.1. United Kingdom
16.3.1.2. Germany
16.3.1.3. Italy
16.3.1.4. France
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. BENELUX
16.3.1.8. Rest of Europe
16.3.2. By Product
16.3.3. By Application
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Product
16.4.2. By Application
16.4.3. By End User
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. United Kingdom Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By Application
16.7.1.2.3. By End User
16.7.2. Germany Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By Application
16.7.2.2.3. By End User
16.7.3. Italy Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By Application
16.7.3.2.3. By End User
16.7.4. France Market Analysis
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Product
16.7.4.2.2. By Application
16.7.4.2.3. By End User
16.7.5. Spain Market Analysis
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast by Market Taxonomy
16.7.5.2.1. By Product
16.7.5.2.2. By Application
16.7.5.2.3. By End User
16.7.6. Russia Market Analysis
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast by Market Taxonomy
16.7.6.2.1. By Product
16.7.6.2.2. By Application
16.7.6.2.3. By End User
16.7.7. BENELUX Market Analysis
16.7.7.1. Introduction
16.7.7.2. Market Analysis and Forecast by Market Taxonomy
16.7.7.2.1. By Product
16.7.7.2.2. By Application
16.7.7.2.3. By End User
17. South Asia Market Analysis 2016 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Billion) and Volume (Units) Analysis By Market Taxonomy, 2016 to 2021
17.3. Current and Future Market Size (US$ Billion) and Volume (Units) Analysis, By Market Taxonomy, 2022 to 2032
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Philippines
17.3.1.5. Thailand
17.3.1.6. Vietnam
17.3.1.7. Rest of South Asia
17.3.2. By Product
17.3.3. By Application
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Product
17.4.2. By Application
17.4.3. By End User
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. India Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By Application
17.7.1.2.3. By End User
17.7.2. Indonesia Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By Application
17.7.2.2.3. By End User
17.7.3. Malaysia Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By Application
17.7.3.2.3. By End User
17.7.4. Philippines Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Product
17.7.4.2.2. By Application
17.7.4.2.3. By End User
17.7.5. Thailand Market Analysis
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast by Market Taxonomy
17.7.5.2.1. By Product
17.7.5.2.2. By Application
17.7.5.2.3. By End User
17.7.6. Vietnam Market Analysis
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast by Market Taxonomy
17.7.6.2.1. By Product
17.7.6.2.2. By Application
17.7.6.2.3. By End User
18. East Asia Market Analysis 2016 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Billion) and Volume (Units) Analysis By Market Taxonomy, 2016 to 2021
18.3. Current and Future Market Size (US$ Billion) and Volume (Units) Analysis, By Market Taxonomy, 2022 to 2032
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Application
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Product
18.4.2. By Application
18.4.3. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. China Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By Application
18.7.1.2.3. By End User
18.7.2. Japan Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By Application
18.7.2.2.3. By End User
18.7.3. South Korea Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Product
18.7.3.2.2. By Application
18.7.3.2.3. By End User
19. Oceania Market 2016 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Historical Market Size (US$ Billion) and Volume (Units) Analysis By Market Taxonomy, 2016 to 2021
19.3. Current and Future Market Size (US$ Billion) and Volume (Units) Analysis, By Market Taxonomy, 2022 to 2032
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Application
19.3.4. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Product
19.4.2. By Application
19.4.3. By End User
19.4.4. Key Market Participants - Intensity Mapping
19.5. Drivers and Restraints - Impact Analysis
19.6. Country-Level Analysis & Forecast
19.6.1. Australia Market Analysis
19.6.1.1. Introduction
19.6.1.2. Market Analysis and Forecast by Market Taxonomy
19.6.1.2.1. By Product
19.6.1.2.2. By Application
19.6.1.2.3. By End User
19.6.2. New Zealand Market Analysis
19.6.2.1. Introduction
19.6.2.2. Market Analysis and Forecast by Market Taxonomy
19.6.2.2.1. By Product
19.6.2.2.2. By Application
19.6.2.2.3. By End User
20. Middle East and Africa (MEA) Market Analysis 2016 to 2021 and Forecast 2022 to 2032
20.1. Introduction
20.2. Historical Market Size (US$ Billion) and Volume (Units) Analysis By Market Taxonomy, 2016 to 2021
20.3. Current and Future Market Size (US$ Billion) and Volume (Units) Analysis, By Market Taxonomy, 2022 to 2032
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Israel
20.3.1.3. Turkey
20.3.1.4. South Africa
20.3.1.5. North Africa
20.3.1.6. Rest of Middle East and Africa
20.3.2. By Product
20.3.3. By Application
20.3.4. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Product
20.4.2. By Application
20.4.3. By End User
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis
20.7. Country-Level Analysis & Forecast
20.7.1. GCC Countries Market Analysis
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast by Market Taxonomy
20.7.1.2.1. By Product
20.7.1.2.2. By Application
20.7.1.2.3. By End User
20.7.2. Israel Market Analysis
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast by Market Taxonomy
20.7.2.2.1. By Product
20.7.2.2.2. By Application
20.7.2.2.3. By End User
20.7.3. Turkey Market Analysis
20.7.3.1. Introduction
20.7.3.2. Market Analysis and Forecast by Market Taxonomy
20.7.3.2.1. By Product
20.7.3.2.2. By Application
20.7.3.2.3. By End User
20.7.4. South Africa Market Analysis
20.7.4.1. Introduction
20.7.4.2. Market Analysis and Forecast by Market Taxonomy
20.7.4.2.1. By Product
20.7.4.2.2. By Application
20.7.4.2.3. By End User
20.7.5. North Africa Market Analysis
20.7.5.1. Introduction
20.7.5.2. Market Analysis and Forecast by Market Taxonomy
20.7.5.2.1. By Product
20.7.5.2.2. By Application
20.7.5.2.3. By End User
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. Bruker Corporation
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Sales Footprint
22.3.1.4. Key Financials
22.3.1.5. Strategy Overview
22.3.1.6. SWOT Analysis
22.3.2. Siemens A.G.
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Sales Footprint
22.3.2.4. Key Financials
22.3.2.5. Strategy Overview
22.3.2.6. SWOT Analysis
22.3.3. General Electric (GE)
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Sales Footprint
22.3.3.4. Key Financials
22.3.3.5. Strategy Overview
22.3.3.6. SWOT Analysis
22.3.4. TriFoil Imaging
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Sales Footprint
22.3.4.4. Key Financials
22.3.4.5. Strategy Overview
22.3.4.6. SWOT Analysis
22.3.5. PerkinElmer, Inc.
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Sales Footprint
22.3.5.4. Key Financials
22.3.5.5. Strategy Overview
22.3.5.6. SWOT Analysis
22.3.6. VisualSonics Inc. (Fujifilm)
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Sales Footprint
22.3.6.4. Key Financials
22.3.6.5. Strategy Overview
22.3.6.6. SWOT Analysis
22.3.7. Mediso Ltd.
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Sales Footprint
22.3.7.4. Key Financials
22.3.7.5. Strategy Overview
22.3.7.6. SWOT Analysis
22.3.8. Agilent Technologies
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Sales Footprint
22.3.8.4. Key Financials
22.3.8.5. Strategy Overview
22.3.8.6. SWOT Analysis
22.3.9. MILabs B.V.
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Sales Footprint
22.3.9.4. Key Financials
22.3.9.5. Strategy Overview
22.3.9.6. SWOT Analysis
22.3.10. MR Solutions
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Sales Footprint
22.3.10.4. Key Financials
22.3.10.5. Strategy Overview
22.3.10.6. SWOT Analysis
22.3.11. Molecules
22.3.11.1. Overview
22.3.11.2. Product Portfolio
22.3.11.3. Sales Footprint
22.3.11.4. Key Financials
22.3.11.5. Strategy Overview
22.3.11.6. SWOT Analysis
23. Assumptions and Acronyms Used
24. Research Methodology
